Reduction of serum X-prolyl dipeptidyl-aminopeptidase activity in tumour-bearing mice and reversal of reduced enzyme activity by lentinan, an anti-tumour polysaccharide.
Serum X-prolyl dipeptidyl-aminopeptidase activity which had been shown to be depressed in cancer patients was clearly reduced in mice with Ehrlich carcinoma and Sarcoma 180, and slightly reduced in mice with methylcholanthrene-induced sarcomas. The reduced enzyme activity was completely reversed during tumour regression of sarcoma 180 by administration of lentinan, which causes regression of sarcoma 180.
D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy / Q000201:enzymology*; D004151:Dipeptides; D010450:Endopeptidases / Q000097:blood*; D005260:Female; D007912:Lentinan / Q000494:pharmacology*; D007931:Leucyl Aminopeptidase / Q000097:blood; D051379:Mice; D009368:Neoplasm Transplantation; D011134:Polysaccharides / Q000494:pharmacology*; D011392:Proline / Q000031:analogs & derivatives; D012510:Sarcoma 180 / Q000188:drug therapy / Q000201:enzymology*; D012513:Sarcoma, Experimental / Q000188:drug therapy / Q000201:enzymology*; D014184:Transplantation, Homologous
D004151:Dipeptides; D011134:Polysaccharides; D007912:Lentinan; D011392:Proline; D010450:Endopeptidases; D007931:Leucyl Aminopeptidase